Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.31 |
| ▸ | USP7 | Q93009 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4773518 | 0.69 | ADORA2A (0.39) | AXLMKNK1MKNK2PDPK1PARP1 | |
| SCHEMBL2733130 | 0.68 | PDPK1 (0.38) | PDPK1ADORA2AADORA1 | |
| SCHEMBL25156828 | 0.66 | KDR (0.38) | AXLMKNK1MKNK2PDPK1PARP1 | |
| SCHEMBL104668 | 0.65 | AXL (0.53) | AXLMKNK1MKNK2PDPK1PARP1 | |
| SCHEMBL29365402 | 0.65 | AXL (0.53) | AXLMKNK1MKNK2PDPK1PARP1 | |
| SCHEMBL23716941 | 0.65 | PDK1 (0.47) | AXLMKNK1MKNK2PDPK1PARP1 | |
| SCHEMBL23716942 | 0.64 | CCNB2 (0.43) | AXLMKNK1MKNK2PDPK1PARP1 | |
| SCHEMBL4037241 | 0.62 | AXL (0.44) | AXLMKNK1MKNK2PDPK1PARP1 | |
| SCHEMBL31324910 | 0.62 | AXL (0.44) | AXLMKNK1MKNK2PDPK1PARP1 | |
| SCHEMBL21393430 | 0.62 | AXL (0.44) | AXLMKNK1MKNK2PDPK1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060142612-A1 | Arylsulfonamide derivatives | MERCK SHARP & DOHME CORP. | 2006-06-29 | — | — | US | claimed |
| EP-1643960-A2 | ARYLSULFONAMIDE DERIVATIVES | Merck & Co., Inc. (US) | 2006-04-12 | — | — | EP | claimed |
| WO-2005004810-A2 | ARYLSULFONAMIDE DERIVATIVES | MERCK & CO., INC. (US) | 2005-01-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142612-A1 | Arylsulfonamide derivatives | BDKRB1, BDKRB2, LTB4R2 | AXL 2161/4885MKNK1 1042/4885MKNK2 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.